DFTX earnings analysis
What we found in DFTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Definium Therapeutics reported a substantially increased net loss of $77.1 million for Q1 2026, marking a 231% increase compared to $23.3 million in the same period last year. The company did not generate any revenue this quarter, which aligns with its ongoing reliance on external funding to support its extensive R&D programs in clinical trials. Management anticipates a robust cash position will sustain operations through 2028, despite escalating operating losses and expenses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Increase in Net Loss
- Net loss rose to $77.1 million in Q1 2026 from $23.3 million in Q1 2025, a 231% increase.
- R&D Expenses Surge
- Research and development expenses increased by 78% year-over-year, from $23.4 million to $41.5 million.
- Liquidity Improvement
- Cash, cash equivalents and investments stood at $373.4 million as of March 31, 2026, sufficient to fund operations until 2028.
- Operational Cash Flow Decline
- Operating cash flow worsened to $(42.6) million in Q1 2026 from $(29.4) million in Q1 2025.
- Increase in G&A Expenses
- General and administrative expenses doubled to $17.7 million, compared to $8.8 million the previous year.
- Interest Income Growth
- Interest income grew to $3.5 million, up from $2.4 million in the same quarter last year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operational Losses
- Net loss of $77.1 million highlights ongoing operational challenges with no revenue generation.
- High Cash Burn Rate
- Cash used in operating activities increased to $42.6 million in Q1 2026, which raises concerns about financial sustainability.
- Dependence on Future Funding
- The company has not generated revenue and is reliant on external financing which could dilute shareholders.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.71
What they said about what is next.
Management expects sufficient cash flow to fund operations into 2028.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Definium Therapeutics (formerly MindMed) is a clinical-stage biopharmaceutical company advancing DT120 (lysergide ODT) through Phase 3 trials for GAD and MDD and developing DT402 (R(-)-MDMA) for ASD. The 10-K highlights…
- 10-Q · July 31, 2025
- MindMed reported sharply higher R&D spend and widening operating losses in Q2 2025. R&D expense rose to $29.8M (Q2 2025) from $14.6M (Q2 2024), driving total operating expense of $40.9M vs $24.5M a year earlier and a Q2…
- 10-Q · May 8, 2024
- MindMed reported a materially stronger liquidity position following an equity raise but materially wider GAAP loss in Q1 2024. Cash and cash equivalents increased to $252,332k (from $99,704k at 12/31/23) largely from…
- 10-K · February 28, 2024
- Mind Medicine (MindMed) reported positive Phase 2b topline results for lead candidate MM120 in GAD (statistically significant, dose-dependent improvement) and is preparing for regulatory interactions and Phase 3…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DFTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever